Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 5/20 | 0.52 |
| ▸ | PIK3CA | P42336 | 9/20 | 0.49 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.46 |
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.43 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.43 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.43 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.42 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.42 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CACNG2 | Q9Y698 | 1/20 | 0.42 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.42 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.42 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1312406 | 0.89 | PIK3CA (0.49) | ROCK2PIK3CAPIK3CDPIK3CGPIK3CB | |
| SCHEMBL1310187 | 0.85 | PIK3CA (0.44) | PIK3CAPIK3CDPIK3CGPIK3CB | |
| SCHEMBL1310263 | 0.82 | PIK3CA (0.65) | PIK3CAPIK3CDPIK3CGMAPK9CSNK1D | |
| SCHEMBL1310487 | 0.82 | ROCK2 (0.51) | ROCK2PIK3CAPIK3CDPIK3CGEGFR | |
| SCHEMBL7913783 | 0.82 | PIK3CA (0.50) | PIK3CAPIK3CDPIK3CGPIK3CBPARP1 | |
| SCHEMBL1311048 | 0.82 | PIK3CA (0.64) | PIK3CAPIK3CDPIK3CGPIK3CBDAPK3 | |
| SCHEMBL1310382 | 0.81 | PIK3CA (0.54) | ROCK2PIK3CAPIK3CDPIK3CGEGFR | |
| SCHEMBL1309827 | 0.81 | PIK3CA (0.61) | PIK3CAPIK3CDPIK3CGPIK3CB | |
| SCHEMBL1309034 | 0.78 | PIK3CA (0.53) | PIK3CAPIK3CDPIK3CGPIK3CBCYP2C9 | |
| SCHEMBL1309866 | 0.76 | PIK3CA (0.55) | ROCK2PIK3CAPIK3CDPIK3CGEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921361-B2 | Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes | UNIVERSITY OF BASEL (CH) | 2014-12-30 | — | — | US | disclosed |
| US-8921361-B2 | Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes | UNIVERSITY OF BASEL (CH) | 2014-12-30 | — | — | US | disclosed |
| US-8921361-B2 | Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes | UNIVERSITY OF BASEL (CH) | 2014-12-30 | — | — | US | disclosed |
| US-20110275762-A1 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIVERSITY OF BASEL (CH) | 2011-11-10 | — | — | US | disclosed |
| US-20110275762-A1 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIVERSITY OF BASEL (CH) | 2011-11-10 | — | — | US | disclosed |
| US-20110275762-A1 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIVERSITY OF BASEL (CH) | 2011-11-10 | — | — | US | disclosed |
| WO-2010052569-A2 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIVERSITY OF BASEL (CH) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275762-A1 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | MTOR, PIK3CA, PIK3CD | ROCK2 1523/4885PIK3CA 2/4885PIK3CD 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.